72 related articles for article (PubMed ID: 31612010)
1. Type-I-IFN-Stimulated Gene TRIM5γ Inhibits HBV Replication by Promoting HBx Degradation.
Tan G; Yi Z; Song H; Xu F; Li F; Aliyari R; Zhang H; Du P; Ding Y; Niu J; Wang X; Su L; Qin FX; Cheng G
Cell Rep; 2019 Dec; 29(11):3551-3563.e3. PubMed ID: 31825835
[TBL] [Abstract][Full Text] [Related]
2. Dicoumarol, an NQO1 inhibitor, blocks cccDNA transcription by promoting degradation of HBx.
Cheng ST; Hu JL; Ren JH; Yu HB; Zhong S; Wai Wong VK; Kwan Law BY; Chen WX; Xu HM; Zhang ZZ; Cai XF; Hu Y; Zhang WL; Long QX; Ren F; Zhou HZ; Huang AL; Chen J
J Hepatol; 2021 Mar; 74(3):522-534. PubMed ID: 32987030
[TBL] [Abstract][Full Text] [Related]
3. Hepatitis B virus X gene mutants emerge during antiviral therapy and increase cccDNA levels to compensate for replication suppression.
Lin CL; Chien RN; Chu YD; Liang KH; Huang YH; Ke PY; Lin KH; Lin YH; Yeh CT
Hepatol Int; 2020 Dec; 14(6):973-984. PubMed ID: 32770306
[TBL] [Abstract][Full Text] [Related]
4. Full-length 5'RACE identifies all major HBV transcripts in HBV-infected hepatocytes and patient serum.
Stadelmayer B; Diederichs A; Chapus F; Rivoire M; Neveu G; Alam A; Fraisse L; Carter K; Testoni B; Zoulim F
J Hepatol; 2020 Jul; 73(1):40-51. PubMed ID: 32087349
[TBL] [Abstract][Full Text] [Related]
5. HBV X protein mutations affect HBV transcription and association of histone-modifying enzymes with covalently closed circular DNA.
Chong CK; Cheng CYS; Tsoi SYJ; Huang FY; Liu F; Fung J; Seto WK; Lai KK; Lai CL; Yuen MF; Wong DK
Sci Rep; 2020 Jan; 10(1):802. PubMed ID: 31964944
[TBL] [Abstract][Full Text] [Related]
6. Interferon-inducible MX2 is a host restriction factor of hepatitis B virus replication.
Wang YX; Niklasch M; Liu T; Wang Y; Shi B; Yuan W; Baumert TF; Yuan Z; Tong S; Nassal M; Wen YM
J Hepatol; 2020 May; 72(5):865-876. PubMed ID: 31863794
[TBL] [Abstract][Full Text] [Related]
7. HAT1 signaling confers to assembly and epigenetic regulation of HBV cccDNA minichromosome.
Yang G; Feng J; Liu Y; Zhao M; Yuan Y; Yuan H; Yun H; Sun M; Bu Y; Liu L; Liu Z; Niu JQ; Yin M; Song X; Miao Z; Lin Z; Zhang X
Theranostics; 2019; 9(24):7345-7358. PubMed ID: 31695772
[No Abstract] [Full Text] [Related]
8. Early and late recurrence after hepatectomy in patients with low-level HBV-DNA hepatocellular carcinoma under antiviral therapy.
Li Z; Tan C; Liu X; Feng Z; Li K
Infect Agent Cancer; 2022 Nov; 17(1):56. PubMed ID: 36397089
[TBL] [Abstract][Full Text] [Related]
9. Antiviral Therapy Reduces Mortality in Hepatocellular Carcinoma Patients with Low-Level Hepatitis B Viremia.
Wang X; Liu X; Wang P; Yu L; Yan F; Yan H; Zhou D; Yang Z
J Hepatocell Carcinoma; 2021; 8():1253-1267. PubMed ID: 34708007
[TBL] [Abstract][Full Text] [Related]
10. Trends in chronic hepatitis B treatment-related research from 1973 to 2018: a bibliometric and visual analysis.
Li G; Lin J; Jiang C; Feng Q; Wen L
J Int Med Res; 2020 Apr; 48(4):300060519893234. PubMed ID: 31878813
[TBL] [Abstract][Full Text] [Related]
11. Hepatitis B virus X protein-elevated MSL2 modulates hepatitis B virus covalently closed circular DNA by inducing degradation of APOBEC3B to enhance hepatocarcinogenesis.
Gao Y; Feng J; Yang G; Zhang S; Liu Y; Bu Y; Sun M; Zhao M; Chen F; Zhang W; Ye L; Zhang X
Hepatology; 2017 Nov; 66(5):1413-1429. PubMed ID: 28608964
[TBL] [Abstract][Full Text] [Related]
12. IFN-α2b inhibits the ethanol enriched-HBV cccDNA through blocking a positive feedback loop of HBx/MSL2/cccDNA/HBV/HBx in liver.
Liu Z; Wang J; Yuan H; Liu L; Bu Y; Zhao M; Yang G; Feng J; Liu Y; Li J; He Q; Zhang X
Biochem Biophys Res Commun; 2020 Jun; 527(1):76-82. PubMed ID: 32446394
[TBL] [Abstract][Full Text] [Related]
13. The novel HBx mutation F30V correlates with hepatocellular carcinoma in vivo, reduces hepatitis B virus replicative efficiency and enhances anti-apoptotic activity of HBx N terminus in vitro.
Salpini R; Surdo M; Cortese MF; Palumbo GA; Carioti L; Cappiello G; Spanò A; Trimoulet P; Fleury H; Vecchiet J; Pasquazzi C; Mirabelli C; Scutari R; Sacco A; Alkhatib M; Missale G; Francioso S; Sarmati L; Andreoni M; Angelico M; Ceccherini-Silberstein F; Levrero M; Perno CF; Belloni L; Svicher V
Clin Microbiol Infect; 2019 Jul; 25(7):906.e1-906.e7. PubMed ID: 30472417
[TBL] [Abstract][Full Text] [Related]
14. Research progress in hepatitis B virus covalently closed circular DNA.
Zhang X; Wang Y; Yang G
Cancer Biol Med; 2021 Dec; 19(4):415-31. PubMed ID: 34931766
[TBL] [Abstract][Full Text] [Related]
15. Identifying and Characterizing Interplay between Hepatitis B Virus X Protein and Smc5/6.
Livingston CM; Ramakrishnan D; Strubin M; Fletcher SP; Beran RK
Viruses; 2017 Apr; 9(4):. PubMed ID: 28368357
[TBL] [Abstract][Full Text] [Related]
16. Antiviral therapy may decrease HBx, affecting cccDNA and MSL2 in hepatocarcinogenesis.
Jin XL; Hong SK; Kim H; Lee SK; Yi NJ; Lee KW; Suh KS
Oncol Lett; 2019 Nov; 18(5):4984-4991. PubMed ID: 31612010
[TBL] [Abstract][Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
